A 28 - 90 Days Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Injection as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia (0991-053)(COMPLETED)

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

May 31, 2006

Study Completion Date

May 31, 2006

Conditions
Fungal Infection
Interventions
DRUG

caspofungin acetate

Cancidas 50 mg dose followed by 70 mg load on day 1 was administered in Indian adults with persistent fever and neutropenia for a maximum duration of empirical treatment from 28 days ((for patients without documented infection) to 90 days (for patients with documented baseline or emergent fungal infection). Patients were treated until the resolution of neutropenia (ANC\>500/mm3), and for up to 72 hours later.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00379964 - A 28 - 90 Days Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Injection as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia (0991-053)(COMPLETED) | Biotech Hunter | Biotech Hunter